The results from their study indicated that antibody-armed activated T-cells can suppress MDSC differentiation and attenuate their suppressive activity via the downregulation of COX2, PGE2, and Arginase-1 pathways, which are potentiated in the presence of Th1 cytokines, suggesting that Th1 enriching immunotherapy may be beneficial in pancreatic cancer treatment [31]. This evidence concerns the gene ARG1 and pancreatic neoplasm.